22 results about "Antigenic Specificity" patented technology

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of (i) glycine at position 13 with aspartic acid or (ii) glutamine at position 61 with arginine. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Disclosed are methods of isolating T cells and TCRs having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Also disclosed are related methods of preparing a population of cells, populations of cells, TCRs, pharmaceutical compositions, and methods of treating or preventing cancer.

Provided herein are computer-implemented methods for training a computational model to predict T cell-antigen specificity and to predict T cell-antigen. Also provided is a system configured to predict T cell-antigen specificity via the computational model tangibly stored on an electronic device. The computational model is trained with a data training set, such as a sparse data training set, that is used as input.

The invention relates to a method for predicting the evolution of an immune response in a subject towards an effector or suppressor response, based on cellular plasticity determined by the cytokine milieu generated after antigenic stimulation. The invention also allows for evaluating the generation of antigen-specific memory regulatory T cells in the evolution of the immune response. The invention also relates to a kit for carrying out the method according to the invention.

A vector harboring nucleic acids encoding a recombinant T cell receptor having antigenic specificity for a DnaJ heat shock protein family member B1-protein kinase cAMP-activated catalytic subunit alpha (DNAJB1-PRKACA) fusion protein is provided, as are host cells and a method for treating fibrolamellar hepatocellular carcinoma with the vector.

The present invention provides a binding protein having antigen specificity for an antigenic peptide / HLA complex, comprising a binding domain containing a T cell receptor (TCR) α chain variable region and a TCR β chain variable region, and uses of the binding protein and pharmaceutical compositions containing the binding protein in the treatment of cancers associated with the antigenic peptide.

The invention provides an application of a mycobacterium tuberculosis antigen Rv1471 in preparation of drugs or vaccines for preventing and / or treating diseases caused by mycobacterium infection. In a cell model, the antigen Rv1471 can promote the maturation of phenotypes and functions of macrophages, and also can mediate training immunity. On the basis, a subunit protein vaccine for expressing the antigen Rv1471 is further constructed. In a mouse immune model, the immunogenicity of the subunit protein vaccine expressing the antigen Rv1471 in a mouse which is not immunized by BCG is measured, and the subunit protein vaccine can promote antigen-specific T cell immune response. In a cell model and an acute infection mouse model, the antigen Rv1471 can provide an effective protection effect against mycobacterium tuberculosis infection. Therefore, the antigen Rv1471 and the subunit vaccine thereof are expected to become a novel preventive / therapeutic tuberculosis vaccine.

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated amino acid sequence encoded by mutated CDKN2A. The TCRs may recognize mutated CDKN2A peptide presented by an HLA-A molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with asp

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with arginine. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

The present application belongs to the technical field of genetic engineering, and particularly relates to a bovine rotavirus group A multi-epitope fusion protein and application thereof. The present application provides a bovine rotavirus group A multi-epitope peptide, fusion protein based on ferritin nanocarriers and application thereof. The multi-epitope peptide is based on bovine rotavirus group A VP4 and VP7 protein sequences, and highly conserved and strong immunogenicity cytotoxic T lymphocyte epitopes, helper T cell epitopes and B cell epitopes are screened by using immunoinformatics technology, and are spliced to form a multi-epitope fusion antigen with good conformational stability. Immunological evaluation shows that the multi-epitope fusion antigen has good antigen specificity and neutralizing activity. Animal experiment results show that the epitope peptide and fusion protein can induce the body to produce high-level neutralizing antibodies against multiple genotypes of BRVA G6, G8 and G10, and significantly improve the broad spectrum and durability of immunoprotection.

Provided are chimeric antigen receptors (CARs) having antigenic specificity for human gamma-delta (γδ) T cell receptor (TCR) constant domain. Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing a condition in a mammal are also provided.

A binding protein having antigen specificity for an antigenic peptide / HLA complex, comprising a binding domain containing a T cell receptor (TCR) alpha chain variable region and a TCR beta chain variable region, and use of the binding protein and a pharmaceutical composition comprising the binding protein in the treatment of cancer associated with the antigenic peptide.

The application provides a recombinant oncolytic virus, a preparation method and a use thereof, wherein the recombinant oncolytic virus is rVSV M51R mIL27, in the application, by introducing IL-27 into the oncolytic vesicular stomatitis virus, on the one hand, the oncolytic vesicular stomatitis virus can be used as a delivery carrier to continuously express IL-27 in the tumor part, improve the effective concentration of IL-27 in the tumor microenvironment, and avoid systemic toxic side effects; on the other hand, IL-27 can synergize with the immune cell death induced by the oncolytic vesicular stomatitis virus to further enhance the antigen-specific T cell response and promote the transformation of tumor-infiltrating lymphocytes from an exhausted state to an effector state. Meanwhile, IL-27 helps to reshape the tumor immune microenvironment by inhibiting the immune suppressive cell population, thereby improving the overall immune response level. Therefore, the recombinant oncolytic virus provided in the application realizes multi-dimensional immune regulation of the tumor microenvironment through virus-mediated targeted delivery and continuous expression, thereby significantly improving the anti-tumor effect of the oncolytic virus therapy.

Disclosed are methods of selectively expanding a number of T cells each having antigenic specificity for a human papillomavirus (HPV) 6 or 11 antigen expressed by a tissue of a mammal. Also disclosed are methods of preparing a T cell product from an HPV 6 or 11 antigen positive papilloma from a mammal. Methods of treating or preventing a condition caused by a chronic HPV 6 or 11 infection in a mammal are also disclosed.

Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of (i) glycine at position 13 with aspartic acid or (ii) glutamine at position 61 with arginine. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Disclosed are methods of isolating T cells having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation, the method comprising: identifying one or more genes in a nucleic acid of a patient cancer cell, each gene containing a cancer-specific mutation encoding a mutated amino acid sequence; inducing autologous APCs of the patient to present the mutated amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs presenting the mutated amino acid sequence; and selecting the autologous T cells. Also disclosed are related methods of making a cell population, a plurality of cell populations, a pharmaceutical composition, and a method of treating or preventing cancer.

The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.

The present invention provides a binding protein having antigen specificity for an antigenic peptide / HLA complex, comprising a binding domain containing a T cell receptor (TCR) α chain variable region and a TCR β chain variable region, and uses of the binding protein and pharmaceutical compositions containing the binding protein in the treatment of cancers associated with the antigenic peptide.